Advertisement
Document › Details
Relief Therapeutics Holding AG. (11/24/21). "Press Release: Relief Reports that Its U.S. Collaboration Partner Has Announced the U.S. Food and Drug Administration has Denied Breakthrough Designation for Aviptadil". Geneva.
Region | United States (USA) | |
Organisation | Relief Therapeutics Holding S.A. (SIX: RLF, OTCQB: RLFTF) | |
Group | Relief Therapeutics (Group) | |
Organisation 2 | FDA (US Food and Drug Administration) | |
Group | United States (govt) | |
Product | aviptadil (NN) | |
Product 2 | drug development | |
Person | Weinstein, Jack (Relief Therapeutics 202010– CFO before Avalon Group + Catalyst Pharmaceuticals + Sterlington Group) | |
RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (“Relief”), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the parent company of its collaboration partner, NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx”), has issued a CEO Update announcing that the U.S. Food and Drug Administration (“FDA”) has denied Breakthrough Therapy Designation (“BTD”) for aviptadil.
NRx noted that BTD is not required for drug approval or emergency use authorization, but can afford faster review times, the ability to submit a rolling application, and dedicated FDA review personnel who may interact more frequently with the sponsor. Additionally, according to the CEO Update, the FDA has already granted priority and rolling review as part of the Fast Track Designation awarded in July 2020. Therefore, the denial does not impede NRx’s ability to seek drug approval, although it does identify areas where NRx needs to seek better scientific alignment with the FDA. The related NRx CEO Update can be accessed through the following link. [ https://www.nrxpharma.com/ceo-update-denial-of-breakthrough-therapy-designation/ ]
ABOUT RELIEF
Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in human patients or a strong scientific rationale. Relief’s lead drug candidate, RLF-100™ (aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S. for the treatment of respiratory deficiency due to COVID-19. As part of its pipeline diversification strategy, in March 2021, Relief entered into a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001. ACER-001 is a taste-masked and immediate release proprietary powder formulation of sodium phenylbutyrate (NaPB) for the treatment of Urea Cycle Disorders and Maple Syrup Urine Disease. In addition, Relief's recently completed acquisitions of APR Applied Pharma Research SA and AdVita Lifescience GmbH, bring to Relief a diverse pipeline of marketed and development-stage programs.
RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF. For more information, visit www.relieftherapeutics.com. Follow us on LinkedIn.
Contact:
RELIEF THERAPEUTICS Holding SA
Jack Weinstein
Chief Financial Officer and Treasurer
contact@relieftherapeutics.com
For media inquiries contact:
Rx Communications Group
Michael Miller
Tel:+1-917-633-6086
mmiller@rxir.com
Investor relations contact:
Rx Communications Group
Michael Miller
Tel:+1-917-633-6086
mmiller@rxir.com
Record changed: 2023-06-05 |
Advertisement
More documents for Relief Therapeutics (Group)
- [1] Relief Therapeutics Holding AG. (1/14/22). "Press Release: Relief Therapeutics Comments on NRx Pharmaceuticals' Press Release Reporting on its Recently Filed Lawsuit". Geneva....
- [2] Relief Therapeutics Holding AG. (1/12/22). "Press Release: Relief Comments on Lawsuit Filed Against It by NeuroRx". Geneva....
- [3] Relief Therapeutics Holding AG. (11/30/21). "Press Release: Relief Therapeutics Announces Executive Changes". Geneva....
- [4] Relief Therapeutics Holding AG. (11/24/21). "Press Release: Relief Therapeutics and InveniAI Sign a Strategic Collaboration Agreement to Identify New Product Development Opportunities using Artificial Intelligence". Geneva....
- [5] Relief Therapeutics Holding AG. (10/7/21). "Press Release: Relief Therapeutics Announces Filing of Lawsuit Against its U.S. Collaboration Partner, NeuroRx, Inc. and its CEO, Dr. Jonathan Javitt, for RLF-100™ (Aviptadil)". Geneva....
- [6] Relief Therapeutics Holding AG. (7/26/21). "Press Release: Relief Therapeutics Announces CHF 15 Million Private Placement (Ad Hoc)". Geneva....
- [7] Relief Therapeutics Holding AG. (5/4/21). "Press Release: Relief and Applied Pharma Research (APR) Sign Binding Term Sheet for Relief to Acquire All Outstanding Shares of APR". Geneva & Balerna....
- [8] Relief Therapeutics Holding AG. (4/19/21). "Press Release: Relief Comments on Certain Statements Made by NeuroRx, Inc. in the Amended Form S-4 Filing of Big Rock Partners Acquisition Corp.". Geneva....
- [9] Relief Therapeutics Holding AG. (4/15/21). "Press Release: Relief Reports 2020 Financial Results and Provides Business Update". Geneva....
- [10] Relief Therapeutics Holding AG. (3/22/21). "Press Release: Relief and Acer Therapeutics Sign Collaboration and License Agreement for Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine D...
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top